JPH0357251Y2 - - Google Patents
Info
- Publication number
- JPH0357251Y2 JPH0357251Y2 JP1987069594U JP6959487U JPH0357251Y2 JP H0357251 Y2 JPH0357251 Y2 JP H0357251Y2 JP 1987069594 U JP1987069594 U JP 1987069594U JP 6959487 U JP6959487 U JP 6959487U JP H0357251 Y2 JPH0357251 Y2 JP H0357251Y2
- Authority
- JP
- Japan
- Prior art keywords
- plaster
- support
- infrared rays
- patch
- effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000919 ceramic Substances 0.000 claims description 15
- 239000011505 plaster Substances 0.000 claims description 14
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 10
- 229910052782 aluminium Inorganic materials 0.000 claims description 10
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical group O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- FDXIVRQIMPXJGE-UHFFFAOYSA-N 2-(2-hydroxybenzoyl)oxyethyl 2-hydroxybenzoate Chemical compound OC1=CC=CC=C1C(=O)OCCOC(=O)C1=CC=CC=C1O FDXIVRQIMPXJGE-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Natural products CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Radiation-Therapy Devices (AREA)
Description
【考案の詳細な説明】
[産業上の利用分野]
この考案は、放射性セラミツクスを含有させた
ことからなる新しいタイプの貼付薬に関する。[Detailed Description of the Invention] [Industrial Application Field] This invention relates to a new type of adhesive patch containing radioactive ceramics.
[従来の技術]
支持体と膏体とを有する貼付薬は、古くから利
用されており、特に打身、捻挫、腰痛、神経痛、
筋肉痛、関節炎などがあつたときには、鎮痛、消
炎の効果を得るために、いわゆる軟膏剤、パツプ
剤などを使用することが行なわれていた。[Prior Art] Patch medicines having a support and a plaster have been used for a long time, and are used especially for bruises, sprains, lower back pain, neuralgia,
When suffering from muscle pain or arthritis, so-called ointments, poultices, etc. have been used to provide pain relief and anti-inflammatory effects.
[考案が解決しようとする問題点]
しかしながら、従来に見られたこの種の貼付薬
は、その構成が比較的単純であることから、当然
のことながらそこから期待される薬効も単一、な
いしは、せいぜい2つの効果を組合せたものに留
まるものであつた。[Problems to be solved by the invention] However, since the composition of this type of patch medicine that has been seen in the past is relatively simple, it goes without saying that the medicinal effect expected from it is only one or only one. , at most it was a combination of two effects.
ところが、例えば最近の腰痛、肩こりなどの原
因には、複合された要因に基づくものが多くなつ
てきており、従来のように単一の原因を取り除く
のみでよいということにはならなくなつた。 However, the causes of back pain, stiff shoulders, etc. these days are increasingly based on multiple factors, and it is no longer sufficient to eliminate a single cause as was the case in the past.
[問題点を解決するための手段]
この考案は、上述のような複合原因を取り除く
ことを可能とする貼付薬について検討を加えた結
果到達したものであつて、ライナ、膏体、支持体
を有する貼付薬において、支持体の外方にアルミ
ニウム層を順に設けると共に、膏体または支持体
に遠赤外線を放射するセラミツクス粉体を分散さ
せていることからなるセラミツクス含有貼付薬、
に関する。[Means for solving the problem] This idea was arrived at as a result of studying a patch that can eliminate the complex causes mentioned above. A ceramic-containing patch comprising an aluminum layer sequentially provided on the outside of the support, and a ceramic powder that emits far infrared rays dispersed in the paste or support;
Regarding.
[作用]
この考案でいう膏体とは、ゴム、プラスチツク
スその他の高分子軟質物質にカンフル、メントー
ル、ハツカ油、サリチル酸メチル、ビタミンE、
グリチルリチル、ノニル酸ワニリルアミドあるい
はその他の消炎あるいは鎮痛に対して効果を示す
薬効成分を含有する軟膏または硬膏を指称してい
るものであり、そのもの自体が有している効果は
公知のものであつてよい。[Function] The plaster referred to in this invention refers to rubber, plastics, and other soft polymer substances containing camphor, menthol, peppermint oil, methyl salicylate, vitamin E,
This refers to an ointment or plaster containing glycyrrhizyl, nonylic acid vanillylamide, or other medicinal ingredients that are effective for anti-inflammatory or analgesic effects, and the effects themselves may be known. .
この膏体の支持体側とは別の面に、ポリエチレ
ン、ポリプロピレンなどのフイルムあるいはその
他の剥離効果を有する紙状物品からなるライナー
をあてがつて、膏体表面を保護するようにしてい
る。 A liner made of a film of polyethylene, polypropylene, or other paper-like material having a peeling effect is applied to the other side of the plaster to protect the surface of the plaster.
また、支持体についても布帛、不織布、紙その
他の繊維材料からなるものであつて、通常の膏体
に使用できるものであれば特に制限はない。 Further, the support is not particularly limited as long as it is made of fabric, nonwoven fabric, paper, or other fibrous material and can be used for ordinary plasters.
この考案では、遠赤外線を放射するセラミツク
ス粉体を前述の膏体ないしは支持体に分散させて
使用するため、セラミツクス層を接着層を介して
断熱層や薬層に接着する必要がなく製造工程が容
易である。ここで使用するセラミツクス粉体につ
いてより具体的に説明すると、ジルコニア系、チ
タニア系あるいはアルミナ系のセラミツクス粉末
であつて、その粒子サイズについては特に限定す
ることを要しないが、この考案の目的である貼付
剤という観点からすれば、できるだけ細かい微粉
末状である方が種々の改変を行なう上で好まし
い。 In this invention, ceramic powder that emits far-infrared rays is dispersed in the above-mentioned plaster or support, so there is no need to adhere the ceramic layer to the heat insulating layer or the chemical layer via an adhesive layer, which simplifies the manufacturing process. It's easy. To explain more specifically about the ceramic powder used here, it is a zirconia-based, titania-based, or alumina-based ceramic powder, and there is no particular restriction on the particle size, but for the purpose of this invention. From the viewpoint of a patch, it is preferable to use the powder in the form of as fine a powder as possible in order to carry out various modifications.
このセラミツクス粉体は、遠赤外線を放射する
材料であり、遠赤外線は、人体の代謝に大きな影
響を与えるものであることが、近年になり各方面
で確認されるようになつてきている。 This ceramic powder is a material that emits far-infrared rays, and in recent years, it has been confirmed in various fields that far-infrared rays have a large effect on the metabolism of the human body.
なお、ここでいう遠赤外線とは、その波長がお
よそ5〜15μmであるものについて指称している
のであつて、この遠赤外線は、皮膚を通して皮下
4〜5cm程度まで浸透することが知られている。 Note that far infrared rays here refer to those whose wavelength is approximately 5 to 15 μm, and it is known that this far infrared rays can penetrate through the skin to about 4 to 5 cm below the skin. .
従つて、遠赤外線が照射されると、血管、リン
パ管あるいは比較的表面に近い筋肉層、神経その
他の細胞組織に対して一様に温熱効果を与えるこ
とになる。 Therefore, when far infrared rays are irradiated, a thermal effect is uniformly exerted on blood vessels, lymph vessels, muscle layers, nerves, and other cell tissues relatively close to the surface.
換言すると、細胞組織に対するミクロなマツサ
ージと分子運動レベルの振動と共鳴の効果を発揮
するものと思われる。 In other words, it is thought to exert microscopic pine surge and vibration and resonance effects at the molecular motion level on cell tissues.
以上のような効果を発揮するセラミツクス粉体
を含有している膏体または支持体からは、その遠
赤外線の放射が支持体の裏面を通して逃散しない
ようにアルミニウム層を設けることを要する。 For plasters or supports containing ceramic powder that exhibit the above-mentioned effects, an aluminum layer must be provided to prevent far-infrared radiation from escaping through the back surface of the support.
なお、このアルミニウム層は、軟質合成樹脂の
フイルムに蒸着したものであつてもよいし、ある
いはまた、アルミニウム箔自体であつてもよい。 Note that this aluminum layer may be deposited on a soft synthetic resin film, or may be the aluminum foil itself.
いずれにしてもアルミニウム層の表面には、こ
の貼付薬を貼付して使用するときに皮膚がむれな
いように、適当箇所に適当数の気孔を設けておく
ことが好ましい。 In any case, it is preferable to provide an appropriate number of pores at appropriate locations on the surface of the aluminum layer so that the skin does not become stuffy when the adhesive patch is used.
[実施例]
以下、この考案の構成および効果について、具
体的な実施例を示しながら、さらに詳細に説明す
る。[Examples] Hereinafter, the configuration and effects of this invention will be described in more detail while showing specific examples.
断面図に示したような構成からなる貼付薬を作
成したが、図中、1はアルミニウム層、2は支持
体、3は膏体、4はライナーを示しているもので
ある。 A patch was prepared having the structure shown in the cross-sectional view, in which 1 is the aluminum layer, 2 is the support, 3 is the plaster, and 4 is the liner.
実施例 1
支持体2としてクラレ4Cクロス(商品名、(株)
クラレ製)を使用しこれにアルミニウム蒸着ポリ
エチレンフイルム1をラミネートしたものを使用
した。Example 1 Kuraray 4C cloth (trade name, manufactured by Co., Ltd.) was used as the support 2.
(manufactured by Kuraray) and laminated with aluminum vapor-deposited polyethylene film 1 was used.
なお、このとき、平均粒径10μmのセラミツク
ス粉末(商品名、セリコールEG−IR8μ)を支持
体に対して30.0g/m2の割合で塗布している。 Note that at this time, ceramic powder (trade name: SERICOL EG-IR8μ) having an average particle size of 10 μm was applied to the support at a rate of 30.0 g/m 2 .
膏体3としては、以下に示した処方に基づいて
得たゲル体を用いて750.0g/m2の比率で支持帯2
上に塗布し、ライナー4としてポリエチレンフイ
ルムを使用してその表面を被覆した。 As the plaster 3, a gel body obtained based on the formulation shown below was used to apply the support band 2 at a ratio of 750.0 g/m2.
A polyethylene film was used as liner 4 to cover the surface.
膏体処方 重量部
サリチル酸メチル 1.5
1−メントール 0.5
d1−カンフル 0.5
濃グリセリン 22.0
ポリソルベート80 0.2
ポリアクリル酸ナトリウム 10.0
カルボキシビニルポリマー 3.0
水酸化アルミニウムゲル 0.7
酸化チタン 3.0
精製水 58.6
実施例 2
支持体2としてナイロンスパボンドベンリーゼ
(商品名、旭化成工業(株)製)を使用し、ライ
ナー4としてシリコーン処理剥離紙を、また、膏
体としては次に示した処方のものを使用した。 Plasme formulation Parts by weight Methyl salicylate 1.5 1-menthol 0.5 d1-camphor 0.5 Concentrated glycerin 22.0 Polysorbate 80 0.2 Sodium polyacrylate 10.0 Carboxy vinyl polymer 3.0 Aluminum hydroxide gel 0.7 Titanium oxide 3.0 Purified water 58.6 Example 2 Nylon as support 2 Supabond Benliese (trade name, manufactured by Asahi Kasei Industries, Ltd.) was used, a silicone-treated release paper was used as the liner 4, and a plaster having the following formulation was used.
膏体処方 重量部
サリチル酸グリコールエステル 5.0
1−メントール 7.0
ノニル酸ワニリルアミド 0.03
ステレンイソプレン共重合ゴム 21.0
テルペン樹脂 11.5
エステルガム 12.5
流動パラフイン 21.07
抗酸化剤 0.1
セリコールEG−IR8μ 21.8
以上のようにして得た2種類の貼付剤は、セラ
ミツクス粉末を使用していないものと比較すると
平均でおよそ30%の改善率が効果の上で認められ
た。 Plasme formulation Parts by weight Salicylic acid glycol ester 5.0 1-menthol 7.0 Nonylic acid vanillylamide 0.03 Sterene isoprene copolymer rubber 21.0 Terpene resin 11.5 Ester gum 12.5 Liquid paraffin 21.07 Antioxidant 0.1 Sericol EG-IR8μ 21.8 2 obtained as above The efficacy of these types of patches was found to be approximately 30% better on average compared to those that did not use ceramic powder.
[考案の効果]
この考案は、ライナー、膏体および支持体の外
方にアルミニウム層を順に設けると共に、膏体
中、支持体中あるいはその中間に遠赤外線を放射
するセラミツクス粉体を分散させていることから
なる放射性セラミツクス含有貼付薬としたことに
より、次の効果を期待することができる。[Effects of the device] This device sequentially provides an aluminum layer on the outside of the liner, the plaster, and the support, and disperses ceramic powder that emits far infrared rays in the plaster, the support, or in between. By using a patch containing radioactive ceramics, the following effects can be expected.
(1) 遠赤外線の人体に対する照射効果が薬効と相
乗的に作用する。(1) The irradiation effect of far infrared rays on the human body works synergistically with the medicinal efficacy.
(2) 体内エネルギーを遠赤外線にかえて再び体内
に変換するものであるから、過熱による副作用
がなく、その薬効も柔らかいものとなる。(2) Since it converts internal energy into far infrared rays and re-converts it back into the body, there are no side effects caused by overheating, and its medicinal effects are gentle.
図面は、この考案の実施例を示した一部断面図
である。
1はアルミニウム層、2は支持体、3は膏体、
4はライナ−。
The drawing is a partially sectional view showing an embodiment of this invention. 1 is an aluminum layer, 2 is a support body, 3 is a plaster body,
4 is liner.
Claims (1)
表面に薬効成分を含む膏体層を展延し、膏体面を
剥離ライナで覆つてなる貼付薬において、 前記膏体層中および/または支持体層中に遠赤
外線を放射する粉末状セラミツクスを分散させた
ことを特徴とするセラミツクス含有貼付薬。[Scope of Claim for Utility Model Registration] A patch drug comprising a plaster layer containing a medicinal ingredient spread on the surface of a support layer lined with an aluminum heat insulating layer, and the plaster surface being covered with a release liner, comprising: A ceramic-containing adhesive patch characterized in that powdered ceramics that emit far-infrared rays are dispersed in the middle and/or the support layer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1987069594U JPH0357251Y2 (en) | 1987-05-12 | 1987-05-12 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1987069594U JPH0357251Y2 (en) | 1987-05-12 | 1987-05-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS63180054U JPS63180054U (en) | 1988-11-21 |
JPH0357251Y2 true JPH0357251Y2 (en) | 1991-12-26 |
Family
ID=30910469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1987069594U Expired JPH0357251Y2 (en) | 1987-05-12 | 1987-05-12 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0357251Y2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5301442B2 (en) * | 2008-04-28 | 2013-09-25 | 利彦 矢山 | External sheet and external sheet set |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0426Y2 (en) * | 1987-01-28 | 1992-01-06 | ||
JPH0418583Y2 (en) * | 1987-02-12 | 1992-04-24 |
-
1987
- 1987-05-12 JP JP1987069594U patent/JPH0357251Y2/ja not_active Expired
Also Published As
Publication number | Publication date |
---|---|
JPS63180054U (en) | 1988-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1164749A (en) | Bandage for administering beneficial drug | |
US6546281B1 (en) | Integrated apparatus for controlled heat aided dermal drug delivery | |
ES2377134T3 (en) | Topical patch-shaped cooling preparation | |
US5008110A (en) | Storage-stable transdermal patch | |
JP4909892B2 (en) | System and method for providing treatment to the body | |
US20070026056A1 (en) | Antiviral patch | |
CN1170360A (en) | Transdermal delivery system with adhesive overlay and peel seal disc | |
CN102000043B (en) | Flurbiprofen salt transdermal patch and preparation method thereof | |
NL8201034A (en) | Bandage for administration of a holy drug. | |
US20130224280A1 (en) | Transdermal compositions and methods for treating stretch marks | |
JPH01265030A (en) | Drup composition containing plant extract and its production | |
CA1309661C (en) | Transdermal delivery system | |
AU738678B2 (en) | Extremely flexible patch having a dermal or transdermal action and process for its production | |
CN203694152U (en) | Medicinal moxa roll patch | |
JP2021020959A (en) | Transdermal therapeutic systems containing lavender oil | |
JPH0357251Y2 (en) | ||
US4812313A (en) | Method for lessening the incidence of anginal attacks | |
JP2004231516A (en) | External gel-like composition, pad material and pad material to be filled in blister container | |
WO2017146096A1 (en) | Adhesive patch | |
JPH0136519Y2 (en) | ||
CN109481422B (en) | Graphene oxide electrothermal film transdermal patch | |
CN108289859A (en) | System and method for cutaneous penetration | |
WO2007062435A2 (en) | Patch | |
KR101144026B1 (en) | Female hormone?containing patch | |
JP2000175960A (en) | Strap |